People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NeuroBo Pharmaceuticals, Inc. | — | Biotechnology | Series B | $93.9M | $49.4M | 2014 |
| ProNAi Therapeutics Inc | — | Biotechnology | Series C | $77.7M | $2.4B | 2012 |
| Opus Genetics, Inc. | — | Biotechnology | Series B | $46.9M | $160.9M | 2020 |
| Biovie Inc. | — | Biotechnology | Series A | $10.5M | $81.1M | 2018 |
| Ocuphire Pharma, Inc. | — | Biotechnology | Seed | $3.9M | $94.4M | 2018 |
Mina Sooch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mina Sooch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Cam Gallagher | 2 | 7 |
| Sean Ainsworth | 2 | 5 |
| James Manuso | 2 | 4 |
| Charles Bisgaier | 2 | 3 |
| Bernhard Hoffmann | 2 | 2 |
| Peter Thompson | 1 | 16 |
| James Topper | 1 | 12 |
| Albert Cha | 1 | 9 |
| Richard J. Berman | 1 | 8 |
| Jonathan Adams | 1 | 7 |
| Alvin Vitangcol | 1 | 5 |
| MICHAEL SHERMAN | 1 | 5 |
| Donald R. Parfet | 1 | 5 |
| Donald Parfet | 1 | 5 |
| DOUGLAS J. SWIRSKY | 1 | 5 |
| Cuong Do | 1 | 4 |
| Andrew I. Koven | 1 | 4 |
| Richard Rodgers | 1 | 4 |
| Terren S. Peizer | 1 | 4 |
| Terren Peizer | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.